EUVIMEDEUVIMED entdecken
Open Access

Optimally Choosing Medication Type for Patients With Opioid Use Disorder

Kara E Rudolph, Nicholas T Williams, Iván Díaz, Sean X Luo, John Rotrosen, Edward V Nunes

American Journal of Epidemiology · 2023

DOI: 10.1093/aje/kwac217 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Epidemiology, 2023. Verfasst von Kara E Rudolph und 5 weiteren Autor:innen. Hauptthemen laut MEDLINE: Opioid-Related Disorders, Buprenorphine. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, National Institute on Drug Abuse.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with opioid use disorder (OUD) tend to get assigned to one of 3 medications based on the treatment program to which the patient presents (e.g., opioid treatment programs tend to treat patients with methadone, while office-based practices tend to prescribe buprenorphine). It is possible that optimally matching patients with treatment type would reduce the risk of return to regular opioid use (RROU). We analyzed data from 3 comparative effectiveness trials from the US National Institute on Drug Abuse Clinical Trials Network (CTN0027, 2006–2010; CTN0030, 2006–2009; and CTN0051 2014–2017), in which patients with OUD (n = 1,459) were assigned to treatment with either injection extended-release naltrexone (XR-NTX), sublingual buprenorphine-naloxone (BUP-NX), or oral methadone. We learned an individualized rule by which to assign medication type such that risk of RROU during 12 weeks of treatment would be minimized, and then estimated the amount by which RROU risk could be reduced if the rule were applied. Applying our estimated treatment rule would reduce risk of RROU compared with treating everyone with methadone (relative risk (RR) = 0.79, 95% confidence interval (CI): 0.60, 0.97) or treating everyone with XR-NTX (RR = 0.71, 95% CI: 0.47, 0.96). Applying the estimated treatment rule would have resulted in a similar risk of RROU to that of with treating everyone with BUP-NX (RR = 0.92, 95% CI: 0.73, 1.11).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Opioid-Related DisordersBuprenorphineHumansNarcotic AntagonistsAnalgesics, OpioidNaltrexoneBuprenorphine, Naloxone Drug CombinationMethadone

Stichwörter der Autor:innen

buprenorphinecausal inferencedoubly robustlassomethadonenaltrexoneopioid use disorderoptimal individualized treatment rules

Substanzen

Narcotic AntagonistsAnalgesics, OpioidNaltrexoneBuprenorphineBuprenorphine, Naloxone Drug CombinationMethadone

Förderung

  • NIDA NIH HHS
  • National Institute on Drug Abuse

Zitieren

APA

Rudolph, K. E., Williams, N. T., Díaz, I., Luo, S. X., Rotrosen, J., & Nunes, E. V. (2023). Optimally Choosing Medication Type for Patients With Opioid Use Disorder. American Journal of Epidemiology. https://doi.org/10.1093/aje/kwac217

Vancouver

Rudolph KE, Williams NT, Díaz I, Luo SX, Rotrosen J, Nunes EV. Optimally Choosing Medication Type for Patients With Opioid Use Disorder. American Journal of Epidemiology. 2023. doi:10.1093/aje/kwac217

BibTeX
@article{Rudolph2023,
  author = {Rudolph, Kara E and Williams, Nicholas T and Díaz, Iván and Luo, Sean X and Rotrosen, John and Nunes, Edward V},
  title = {Optimally Choosing Medication Type for Patients With Opioid Use Disorder},
  journal = {American Journal of Epidemiology},
  year = {2023},
  doi = {10.1093/aje/kwac217}
}
Kostenlos starten →